Uncategorized
Study Published in Journal of Glaucoma Evaluates a Single Glaukos iStent® Trabecular Micro-Bypass Stent as a Standalone Procedure
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study published recently in the Journal of Glaucoma showed that a single iStent® Trabecular Micro-Bypass Stent significantly reduced intraocular pressure (IOP) when implanted as a standalone procedure in pseudophakic eyes wi